Spybiotech
Develops vaccines against infectious diseases and cancer using its SpyTag/SpyCatcher protein superglue platform
Highlights
- New on EvolcAdded 2026-10-28
About Spybiotech
SpyBiotech is a clinical-stage company that develops vaccines against infectious diseases and cancer. Its platform is the proprietary SpyTag/SpyCatcher protein "superglue" technology, for which it holds exclusive rights in vaccinology. Its lead candidate, SPYVLP01, targets cytomegalovirus (CMV), and the company reported completing enrollment in a Phase I trial of it in 2024.
The company develops its own vaccine candidates and also licenses in candidates and technology. It signed an exclusive global licensing agreement with Serum Institute of India for a virus-like-particle vaccine against COVID-19, and a collaboration agreement for a VLP vaccine candidate against Epstein-Barr virus. It has raised a $32.5 million Series A round.
SpyBiotech was founded in 2017 and spun out of the University of Oxford, where it is headquartered. It has an office in Cambridge, Massachusetts, in the United States. The SpyTag/SpyCatcher technology is stated to be used by research scientists in over 30 countries.
Product: SpyTag/SpyCatcher protein superglue vaccine platform and clinical-stage vaccine candidates, including SPYVLP01 against CMV.
Jobs at Spybiotech
Leadership
- Jing Jin · Co-founderSource: company website
- Mark Howarth · Co-founderSource: company website
- Simon Draper · Co-founderSource: company website
- Sumi Biswas · President, Co-founder; Chief Scientific OfficerSource: company website
- Mark Leuchtenberger · Chief Executive Officer (CEO)Source: company website
- Keith Dewedoff · Chief Financial Officer & Corporate DevelopmentSource: company website
More biotech & pharma companies
Sterling Pharma Solutions
Develops and manufactures active pharmaceutical ingredients for biotech and pharmaceutical companiesNew on EvolcStorm Therapeutics
Clinical-stage biotech developing small-molecule RNA modifying enzyme inhibitors for cancer and other diseasesNew on EvolcSygnature Discovery
Contract drug discovery services for biotech and pharma firms, spanning chemistry, biology, structural work and preclinical studiesNew on EvolcSynthace
Experiment design, lab automation and AI-ready data software for drug discovery and life science R&D teamsNew on EvolcT-Cypher Bio
Develops immune engager drugs for cancer and autoimmune diseases, built on proprietary wet-lab and computational platformsNew on EvolcTheolytics
Develops oncolytic adenovirus immunotherapies for patients with solid tumours and cancers of high unmet needNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Cloudflare
- CookieYes
- Elementor
- WordPress
- jQuery